share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K.

Novavax | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K.

諾瓦瓦克斯醫藥 | 4:持股變動聲明-董事 King Rachel K.
美股SEC公告 ·  06/14 13:30

Moomoo AI 已提取核心訊息

Rachel K. King, associated with Novavax Inc [NVAX], completed a transaction on June 12, 2024, acquiring 6,670 shares of common stock at no cost. This transaction was classified as an exercise or conversion of derivative security, under the transaction code 'M'. Following this acquisition, King's direct holdings in Novavax common stock increased to a total of 18,920 shares. The transaction has been marked as completed.
Rachel K. King, associated with Novavax Inc [NVAX], completed a transaction on June 12, 2024, acquiring 6,670 shares of common stock at no cost. This transaction was classified as an exercise or conversion of derivative security, under the transaction code 'M'. Following this acquisition, King's direct holdings in Novavax common stock increased to a total of 18,920 shares. The transaction has been marked as completed.
2024年6月12日,諾瓦瓦克斯醫藥(Novavax Inc [NVAX])的Rachel K. King獲得了6,670股普通股,無需支付任何費用。此次交易歸類爲衍生證券的行權或轉換,交易代碼爲“M”。在此次收購之後,King在諾瓦瓦克斯醫藥普通股的直接持股增加到了18,920股。交易已標記爲已完成。
2024年6月12日,諾瓦瓦克斯醫藥(Novavax Inc [NVAX])的Rachel K. King獲得了6,670股普通股,無需支付任何費用。此次交易歸類爲衍生證券的行權或轉換,交易代碼爲“M”。在此次收購之後,King在諾瓦瓦克斯醫藥普通股的直接持股增加到了18,920股。交易已標記爲已完成。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息